Lv7
4860 积分 2020-03-29 加入
加油加油加油！
Neoadjuvant Chemoimmunotherapy for NSCLC
11小时前
待确认
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
11小时前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
11小时前
已完结
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
1天前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
24天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
26天前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
26天前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
26天前
已完结
Deep Learning Radiomics Model of Dynamic Contrast‐Enhanced MRI for Evaluating Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma
2个月前
已完结
Review and Comparative Analysis of Machine Learning-based Predictors for Predicting and Analyzing Anti-angiogenic Peptides
4个月前
已完结
皖公网安备34019202002308
